Solopharm, a leading Russian pharmaceutical company, announces the launch of a new high-tech facility for the production of pre-filled syringes and vials with hyaluronic acid. A crucial milestone was the development of its own proprietary technology for producing cross-linked hyaluronic acid.
Cross-linked hyaluronic acid is the result of a complex technological process (cross-linking) that allows for the creation of stable gel preparations with prolonged action and high elasticity. These are effectively used in injectable cosmetology as well as in rheumatology and traumatology.
«We have gone through a difficult journey of more than two years to develop the technology for cross-linking hyaluronic acid. A significant amount of time was required to develop both the analytical methods for determining the quantitative content of cross-linked hyaluronic acid and the cross-linking agent BDDE, and the microbiological methods for controlling bacterial endotoxins and sterility. This enables us to produce high-quality and safe drugs.
Thanks to our cohesive team of highly qualified specialists, we are mastering new and complex technologies to offer the medical community and patients Russian products of the highest quality that meet all GMP standards», noted the company's CEO, Mamuka Mikhelashvili.
The investment in the project amounted to 400 million rubles. The launch of products based on cross-linked hyaluronic acid will allow the company to expand its presence in the aesthetic medicine market by launching a line of fillers, as well as to offer patients advanced solutions in areas such as orthopedics, rheumatology, traumatology, and surgery.
